A detailed history of Schonfeld Strategic Advisors LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 673,838 shares of RCUS stock, worth $10.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
673,838
Previous 232,794 189.46%
Holding current value
$10.8 Million
Previous $3.55 Million 190.61%
% of portfolio
0.07%
Previous 0.02%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $6.04 Million - $7.94 Million
441,044 Added 189.46%
673,838 $10.3 Million
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $1.88 Million - $2.38 Million
128,934 Added 124.14%
232,794 $3.55 Million
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $1.88 Million - $2.56 Million
-126,960 Reduced 55.0%
103,860 $1.96 Million
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $1.18 Million - $1.73 Million
87,920 Added 61.53%
230,820 $4.41 Million
Q3 2023

Nov 14, 2023

SELL
$17.62 - $23.54 $706,984 - $944,518
-40,124 Reduced 21.92%
142,900 $2.57 Million
Q2 2023

Aug 14, 2023

SELL
$16.97 - $22.03 $1.88 Million - $2.44 Million
-110,786 Reduced 37.71%
183,024 $3.72 Million
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $2.23 Million - $3.23 Million
139,471 Added 90.37%
293,810 $5.36 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $467,106 - $846,719
23,711 Added 18.15%
154,339 $3.19 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $812,120 - $1.05 Million
-34,960 Reduced 21.11%
130,628 $3.42 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $2.85 Million - $6.25 Million
165,588 New
165,588 $4.2 Million
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $720,108 - $1.04 Million
-24,900 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $15,690 - $24,235
500 Added 2.05%
24,900 $1.01 Million
Q3 2021

Nov 16, 2021

BUY
$26.93 - $37.68 $657,092 - $919,392
24,400 New
24,400 $851,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $1.15 Million - $1.81 Million
-50,701 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$26.16 - $41.39 $917,588 - $1.45 Million
35,076 Added 224.49%
50,701 $1.42 Million
Q4 2020

Feb 16, 2021

BUY
$17.0 - $32.36 $265,625 - $505,625
15,625 New
15,625 $406,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.